Edesa Biotech reported $7.2 million net loss for 2025, with $10.4 million in working capital. Plans for Phase 2 study.

Edesa Biotech, Inc. reported its financial results for the fiscal year ending September 30, 2025. The company initiated manufacturing activities for a Phase 2 study on EB06, a dermatology drug candidate for vitiligo. Its respiratory program showed positive results in a Phase 3 study of paridiprubart (EB05). Total operating expenses increased to $7.9 million compared to $7.0 million in the prior year. The company reported a net loss of $7.2 million for 2025. Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million as of September 30, 2025. They received $3.4 million from a share offering after the fiscal year end. Key priorities include executing the Phase 2 vitiligo study and advancing respiratory assets. The company plans to participate in JP Morgan week starting January 12, 2026. Edesa Biotech is focusing on developing therapies for immuno-inflammatory diseases, specifically in Medical Dermatology and Respiratory areas. The company is seeking non-dilutive funding, partnership opportunities, and regulatory approvals.